IMR Press / EJGO / Volume 25 / Issue 1 / pii/2004111

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research

Taxanes in the first-line chemotherapy of metastatic breast cancer: Review

Show Less
1 Department of Obstetrics and Gynecology of the University-Hospital Schleswig-Holstein, Campus Luebeck, Baden (Gennany)
2 Department of Obstetrics and Gynecology, Baden (Gennany)
Eur. J. Gynaecol. Oncol. 2004, 25(1), 66–70;
Published: 10 February 2004

Taxanes belong to the most effective agents in the treatment of advanced and non-hormone responsive breast cancer. Several recently published phase III studies have examined the role of taxane-anthracycline combinations in the first line treatment of metastatic breast cancer. Especially, patients with symptomatic visceral spread seem to benefit from taxanes containing poly­chemotherapy that is adequately dosed. Polychemotherapy with taxanes appears to be more effective than monotherapy. But at present, there are no adequate data concerning the comparison of taxane-monotherapy and anthracycline-containing poly­chemotherapy. New hopeful results with respect to efficacy and toxicity are reported from the docetaxel-capecitabine poly­chemotherapy. Thus, the combination of anthracyclines (adriamycin, doxorubicin) and taxanes (docetaxel, paclitaxel) is a promis­ing tool in the treatment of metastatic breast cancer. New interesting combinations are under investigation.

Breast cancer
Back to top